This downregulation of sclerostin is consistent with increased liver lipid levels, indicating its role in the liver lipid-bone metabolism axis and its practical value as a marker of NAFLD (Zhou et al., 2021). The gene discussed is SOST; the disease is metabolic dysfunction-associated steatotic liver disease.